{"id":1207,"date":"2026-10-23T08:34:18","date_gmt":"2026-10-23T11:34:18","guid":{"rendered":"https:\/\/www.vitapharmaconsulting.com\/en\/?post_type=noticias&p=1207"},"modified":"2026-10-23T08:42:30","modified_gmt":"2026-10-23T11:42:30","slug":"mhra-withdraws-marketing-authorization-of-ixchiq-vaccine-following-safety-review","status":"publish","type":"noticias","link":"https:\/\/www.vitapharmaconsulting.com\/en\/news\/2026\/10\/23\/mhra-withdraws-marketing-authorization-of-ixchiq-vaccine-following-safety-review\/","title":{"rendered":"MHRA Withdraws Marketing Authorization of IXCHIQ Vaccine Following Safety Review"},"content":{"rendered":"

On October 20, 2026, the UK regulatory agency (MHRA) announced, in its <\/span>Drug Safety Update<\/span><\/i>, the withdrawal of the marketing authorization of the IXCHIQ chikungunya vaccine, held by Valneva. In the Brazilian context, <\/span>Instituto Butantan<\/span><\/a> acts in partnership with Valneva and holds the marketing authorization and the local manufacturing authorization, both approved by ANVISA.<\/span><\/p>\n

<\/p>\n

The MHRA decision followed the advice of the Commission on Human Medicines (CHM), an advisory public body in the United Kingdom, sponsored by the Department of Health and Social Care, and rests on the conclusion that the benefit-risk balance of the product is no longer favorable. The vaccine is being removed only from the UK market.<\/span><\/p>\n

A few days before the MHRA\u2019s decision, <\/span>Valneva had already published an update regarding the situation in the UK<\/span><\/a>, clarifying that this withdrawal does not affect marketing authorizations approved in other territories, such as the European Union, Canada, and Brazil.<\/span><\/p>\n

What motivated the decision<\/h2>\n

IXCHIQ is a live attenuated vaccine indicated for the prevention of chikungunya virus infection in adults traveling to high-risk areas. According to the MHRA, the review of post-authorization safety data identified serious adverse reactions, including chikungunya-like symptoms and rare neurological events such as encephalitis. The cases occurred predominantly in older adults and in people with underlying medical conditions, but also in individuals with no other known conditions, and some resulted in hospitalization or death. On this basis, the Agency concluded that, for UK travelers, the benefits of the vaccine no longer outweigh the risks.<\/span><\/p>\n

Advice to healthcare professionals<\/h2>\n

The MHRA advises UK healthcare professionals to:<\/span><\/p>\n